Table 2.
IT type | Cancer | Study | Phase | Target | Formulation | Combination |
---|---|---|---|---|---|---|
CAR | Solid tumors | NCT04981691 | Phase I | MESO | EP autologous T cells | NA |
Vaccine | NSCLC, CRC, PDAC | NCT03948763 | Phase I | KRAS | V941 mRNA | Pembrolizumab |
siRNA (CAS3/SS3) | B-cell NHL | NCT04995536 | Phase I | TLR9, STAT3 | siRNA linked to CpG oligonucleotide | Radiotherapy |
Synthetic naked mRNA | BC | NCT03788083 | Phase I | TriMix | NA | NA |
Vaccine | OC | NCT04163094 | Phase I | 3 OC TAA | LNP | Carboplatin/paclitaxel |
Vaccine | Esophageal, NSCLC | NCT03908671 | Pilot study | Neoantigen | Undisclosed | NA |
Vaccine | Melanoma | NCT03897881 | Phase II | Neoantigen | LNP | Pembrolizumab |
Vaccine | Solid tumors | NCT03313778 | Phase I | Neoantigen | LNP | Pembrolizumab |
Vaccine | Melanoma | NCT03815058 | Phase II | Neoantigen | RNA-LPX | Pembrolizumab |
Vaccine | Melanoma | NCT02410733 | Phase I | 4 TAA | RNA-LPX | NA |
Vaccine | Prostate | NCT04382898 | Phase I/II | 5 PC TAA | LNP | Cemiplimab |
Vaccine | Esophageal, gastric cancer, CRC, PC | NCT03468244 | Pilot study | Neoantigen | Undisclosed | NA |
Vaccine | GBM | NCT03688178 | Phase II | CMV pp65 | mRNA-Loaded autologous DC | Varlilumab |
Vaccine | GBM | NCT02649582 | Phase I/II | WT-1 | mRNA-Loaded autologous DC | Temozolomide |
Vaccine | NSCLC | NCT03164772 | Phase I/II | 6 NSCLC TAA | BI 1361849 | Durvalumab, tremelimumab |
Vaccine | Melanoma | NCT01456104 | Phase I | Melanoma TAA | Autologous LC EP with TAA mRNA | NA |
Vaccine | GBM | NCT03927222 | Phase II | CMV | Pp65-LAMP mRNA-loaded autologous DC | Temozolomide, GM-CSF Tetanus-diphteria, toxoid |
Vaccine | GMB | NCT02465268 | Phase II | CMV | Pp65-shLAMP mRNA-loaded DC | GM-CSF |
Vaccine | Brain metastasis | NCT02808416 | Phase II | Neoantigen | mRNA tumor antigen pulsed DC | NA |
Vaccine | GBM | NCT00639639 | Phase I | CMV | Pp65-LAMP mRNA-loaded autologous DC | Tetanus toxoid |
Vaccine | PC | NCT01197625 | Phase I/II | Tumor antigen | Tumor mRNA-loaded DC | hTERT Survivin |
Vaccine | AML | NCT01686334 | Phase I/II | WT1 antigen | mRNA EP autologous DC | (Potentially) low-dose chemotherapy |
Vaccine | MM | NCT01995708 | Phase I | CT7, MAGE-A3, WT1 | mRNA EP autologous LC | Standard of care |
Vaccine | AML, HRMS | NCT03083054 | Phase I/II | WT1 antigen | mRNA EP autologous DC | NA |
Vaccine | NSCLC, GEA, mUC, MSS-CRC | NCT03639714 | Phase I/II | Neoantigen | SAM | ChAd, nivolumab, ipilimumab |
Vaccine | MSS-CRC, NSCLC, PDAC | NCT03953235 | Phase I/II | Shared neoantigen Kras | SAM | ChAd, nivolumab, ipilimumab |
Vaccine | CRC | NCT05141721 | Phase II/III | Neoantigen | SAM | ChAd, standard of care atezolizumab, ipilimumab |
RNAi | PDAC | NCT01676259 | Phase II | KRAS | siG12D-LODER | Gemcitabine, paclitaxel, FOLFIRINOX |
RNAi | Advanced malignant solid neoplasms | NCT01591356 | Phase I | EPHA2 | DOPC encapsulation | NA |
Vaccine | Melanoma | NCT02410733 | Phase I | NYESO-1, MAGE A3 tyrosinase, TPTE | Lipo-MERIT | NA |
Vaccine | Melanoma | NCT03815058 | Phase II | Neoantigen | Lipoplex | Pembrolizumab |
mAB | Solid tumors | NCT04683939 | Phase I/II | CLDN18.2 | Undisclosed | Paclitaxel, gemcitabine |
Immune inducers | Solid tumors, lymphoma | NCT03739931 | Phase I/II | NA | OX40L, IL23, IL36y coding mRNA | Durvalumab |
Abbreviations: BC, breast cancer; ChAd, chimpanzee adenovirus; CMV, cytomegalovirus; EP, electroporated; GBM, glioblastoma multiforme; GEA, gastroesophageal adenocarcinoma; HRMS, high-risk myelodysplastic syndrome; IT, immunotherapy; LCs, Langerhans cells; AML, acute myeloid leukemia; MESO, mesothelin; MSS-CRC, microsatellite stable colorectal cancer; mUC, metastatic urothelial carcinoma; NA, not applicable; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung carcinoma; OC, ovarian cancer; PC, prostate cancer; PDAC, pancreatic ductal adenocarcinoma; pHGG, pediatric high-grade glioma; STAT3, signal transducer and activator of transcription 3; TAA, tumor-associated antigens; TLR9, Toll-like receptor 3.